N@N

MRX, CPTS, HGSI, MDVN, HLX, KGC Are Seasonally Ripe To Go Up In the Next Five Weeks

August 5, 2011 / M2 PRESSWIRE / BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of MEDICIS PHARMACEUTICAL-CL A (NYSE:MRX), CONCEPTUS INC (NASDAQ:CPTS), HUMAN GENOME SCIENCES INC (NASDAQ:HGSI), MEDIVATION INC (NASDAQ:MDVN), HELIX ENERGY SOLUTIONS GROUP (NYSE:HLX), KINROSS GOLD CORP (NYSE:KGC) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: http://www.squeezetrigger.com/services/strat/mh.php

The following stocks are expected to go Up:

     Symbol     Company                             Expected Return     Odds                    By The Following Date
     MRX        MEDICIS PHARMACEUTICAL-CL A         12.69%              89.47% (17 of 19)       Wednesday, August 31st 2011
     CPTS       CONCEPTUS INC                       10.39%              80.00% (12 of 15)       Thursday, August 25th 2011
     HGSI       HUMAN GENOME SCIENCES INC           9.89%               82.35% (14 of 17)       Thursday, August 25th 2011
     MDVN       MEDIVATION INC                      17.63%              85.71% (6 of 7)         Thursday, September 15th 2011
     HLX        HELIX ENERGY SOLUTIONS GROUP        10.21%              71.43% (10 of 14)       Tuesday, September 13th 2011
     KGC        KINROSS GOLD CORP                   10.53%              68.42% (13 of 19)       Friday, September 16th 2011

MEDICIS PHARMACEUTICAL-CL A (NYSE:MRX) - Medicis Pharmaceutical Corporation, a specialty pharmaceutical company, engages in the development and marketing of products for the treatment of dermatological and aesthetic conditions in the United States, Canada, and Europe. The companys products address various conditions or aesthetic improvements, including facial wrinkles, glabellar lines, acne, fungal infections, rosacea, hyperpigmentation, photoaging, psoriasis, seborrheic dermatitis, and cosmesis. Its primary products include DYSPORT for temporary improvement in the appearance of glabellar lines in adults younger than 65 years of age; LIPOSONIX to destroy targeted fat just beneath the skin in the treatment of the anterior abdomen; PERLANE and RESTYLANE for the correction of facial wrinkles and folds, such as nasolabial folds; SOLODYN for the treatment of inflammatory lesions of non-nodular acne vulgaris in patients 12 years of age and older; TRIAZ for the topical treatment of acne vulgaris; VANOS, a topical corticosteroid for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses in patients 12 years of age or older; and ZIANA, a topical treatment of acne vulgaris in patients 12 years of age and older. The company sells its products primarily to wholesale pharmaceutical distributors and retail pharmacy chains. It has strategic collaborations with Glenmark; Revance Therapeutics, Inc.; Hyperion Therapeutics, Inc.; Perrigo Israel Pharmaceuticals Ltd.; and IMPAX Laboratories, Inc. The company was founded in 1987 and is headquartered in Scottsdale, Arizona.

CONCEPTUS INC (NASDAQ:CPTS) - Conceptus, Inc. designs, develops, and markets minimally invasive devices for reproductive medical applications. It offers Essure, a permanent birth control system for women. The Essure system delivers a micro-insert into a woman's fallopian tubes, causing benign tissue in-growth that blocks the fallopian tubes. The company distributes its products through direct sales force and distributor networks primarily to physicians and hospitals. It primarily operates in the United States, France, and the rest of Europe. Conceptus, Inc. was founded in 1992 and is headquartered in Mountain View, California.

HUMAN GENOME SCIENCES INC (NASDAQ:HGSI) - Human Genome Sciences, Inc. operates as a biopharmaceutical company. Its principal products in development include BENLYSTA for systemic lupus erythematosus; and raxibacumab for inhalation anthrax. The companys mid- and early-stage pipeline products comprise Mapatumumab for the treatment of non-small cell lung cancer, multiple myeloma, and hepatocellular cancer; IAP Inhibitors that are compounds, which block the activity of IAP (inhibitor of apoptosis) proteins, allowing apoptosis to proceed and causing the cancer cells to die; and CCR5 mAb, a human monoclonal antibody to the CCR5 receptor for the treatment of ulcerative colitis. Human Genome Sciences, Inc. also holds financial rights to certain products in the GlaxoSmithKline clinical development pipeline, including darapladib, a Phase III clinical trial product for the treatment of coronary heart disease and ischemic stroke; and Albiglutide for the treatment for type 2 diabetes, which is in Phase III clinical trial stage. The company has a license agreement with GlaxoSmithKline for the co-development and commercialization of BENLYSTA; and a collaboration and license agreement with Aegera Therapeutics, Inc. to develop and commercialize certain oncology molecules and related backup compounds. Human Genome Sciences, Inc. was founded in 1992 and is headquartered in Rockville, Maryland.

MEDIVATION INC (NASDAQ:MDVN) - Medivation, Inc., a biopharmaceutical company, focuses on the development of small molecule drugs for the treatment of Alzheimers disease, Huntington disease, and castration-resistant prostate cancer. The companys product candidates under clinical development include Dimebon, which is in Phase III clinical trial for the treatment of Alzheimers disease and Huntington disease; and MDV3100, which is in Phase III clinical trial for the treatment of castration-resistant prostate cancer. It has collaboration agreements with Pfizer Inc to develop and commercialize Dimebon; and Astellas Pharma Inc. to develop and commercialize MDV3100. The company was founded in 2003 and is based in San Francisco, California.

HELIX ENERGY SOLUTIONS GROUP (NYSE:HLX) - Helix Energy Solutions Group, Inc. operates as an offshore energy company. It provides development solutions and various other contracting services to the energy market, as well as to its oil and gas properties. The company provides a range of contracting services primarily in the Gulf of Mexico, North Sea, the Asia Pacific, and West Africa regions primarily in deepwater. It offers development services comprising installation of subsea pipelines, flowlines, control umbilicals, manifolds, and risers; pipelay and burial; installation and tie-in of riser and manifold assembly; commissioning, testing, and inspection services; and cable and umbilical lay and connection. The company also provides various production services, including inspection, repair, and maintenance of production structures, risers, pipelines, and subsea equipment; well intervention; life of field support; and intervention engineering. In addition, it offers decommissioning and remediation services; plugging and abandonment services; platform salvage and removal services; pipeline abandonment services; and site inspections. Further, the company engages in the exploration, development, and production of oil and gas properties located primarily in the Gulf of Mexico. It offers its products and services to independent oil and gas producers and suppliers, pipeline transmission companies, and offshore engineering and construction firms. As of December 31, 2009, it had 578 billion cubic feet equivalent of estimated proved reserves. The company was formerly known as Cal Dive International, Inc. and changed its name to Helix Energy Solutions Group, Inc. in March 2006. Helix Energy Solutions Group was founded in 1990 and is headquartered in Houston, Texas.

KINROSS GOLD CORP (NYSE:KGC) - Kinross Gold Corporation, together with its subsidiaries, engages in mining and processing gold ores. It also involves in the exploration and acquisition of gold bearing properties. The companys gold production and exploration activities are carried out principally in the Americas, Africa, and the Russian Federation. As of December 31, 2010, its proven and probable mineral reserves were 62.4 million ounces of gold, 90.9 million ounces of silver, and 1.4 billion pounds of copper. The company was founded in 1972 and is based in Toronto, Canada.

SqueezeTrigger.com has built a massive database that collects, analyzes and publishes multiple proprietary trading strategies that predict price moves in stocks, commodities and currencies. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of each of the strategies highlighted. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com

www.squeezetrigger.com monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO.

INVESTMENTS & TRADING

SqueezeTrigger -- 25 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

About SQUEEZETRIGGER.COM

WWW.SQUEEZETRIGGER.COM is a service designed to help bonafide shareholders of publicly traded US companies fight short selling. SqueezeTrigger.com has built a proprietary database that uses Threshold list feeds and short sale time and sale data from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short trades.

SQUEEZETRIGGER.COM has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2.5 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha'a"s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.

All material herein was prepared by SQUEEZETRIGGER.COM, based upon information believed to be reliable. The information contained herein is not guaranteed by SQUEEZETRIGGER.COM to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion.

Occassionally companies pay $995.00 to purchase data for information provided in reports issued by BUYINS.NET, a company affiliated with SQUEEZETRIGGER.COM. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SQUEEZETRIGGER.COM is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. SQUEEZETRIGGER.COM will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

SQUEEZETRIGGER.COM and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of SQUEEZETRIGGER.COM, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.

By visiting SQUEEZETRIGGER.COM or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. Global Automated Trading Systems, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to SQUEEZETRIGGER.COM and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State.

Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. SQUEEZETRIGGER.COM does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. SQUEEZETRIGGER.COM places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.

Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SQUEEZETRIGGER.COM undertakes no obligation to update such statements.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.

Contact: Thomas Ronk, CEO www.squeezetrigger.com +1-800-715-9999 Tom@squeezetrigger.com

SqueezeTrigger is a registered trademark, Reg. No. 3,120,641